representative work

MediPharm Labs Inc. Enters into $38.7 Million Credit Facility with Schedule 1 Bank


On October 10, 2019, a Schedule 1 bank (the “Bank”) entered into a $38.7 million credit agreement with MediPharm Labs Inc., a company specializing in the production of purified, pharmaceutical-grade cannabis oil and concentrates and advanced derivative products and the wholly-owned operating subsidiary of MediPharm Labs Corp., a TSX-listed company. The credit agreement provides for aggregate credit facilities of $38.7 million, comprised of a $25 million revolving term facility, a $5.7 million non-revolving term facility and an $8 million non-revolving delayed draw term facility.

Cassels acted for the Bank, with a team that included Peter Sullivan, Bryan Woodman, Daniel Cipollone and Paras Patel (Financial Services), Jonathan Sherman (Cannabis), Ardy Mohajer (Real Estate) and Steven Kennedy (Intellectual Property).